Kravos Tramšek

1 Introduction Type 2 diabetes mellitus is a chronic disease that is estimated to affect 510.8 million people by 2030. Based on projections, global insulin consumption is expected to rise from 516.1 million 1,000 IU vials annually in 2018, to 633.7 million vials annually by 2030 (1). Guidelines recommend adding glucose-lowering treatments step by step according to HbA1c to control glycemia, which significantly impacts the frequency of complications associated with the disease (2).

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.